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Abstract 
 Hürthle cell tumors are a particular group of tumors of the thyroid gland composed 
exclusively or predominantly by Hürthle or oncocytic cells, characterized by their consistent 
excessive mitochondrial number, structurally and functionally abnormal. Our group have 
recently described an overall increase of "mitochondria-shaping" proteins in Hürthle cell 
tumors, suggesting a role for abnormal mitochondrial biogenesis in Hürthle cell 
transformation. From those proteins, DRP1, a member of the dynamin family GTPases 
required for mitochondrial fission, appears to be one of the most overexpressed in Hürthle 
cells tumors, a pattern which has also been described in other non-oncocytic tumors. A 
recent study demonstrated that UCP2, a member of a larger family of mitochondrial anion 
carrier proteins and a key modulator of mitochondrial reactive oxygen species, regulates 
mitochondrial fission process, through DRP1 expression regulation. 
 In the present study, we intended to assess UCP2 and DRP1 expression, by 
immunohistochemistry analysis, in larger series of 245 thyroid carcinomas, with and without 
Hürthle cells, and correlate UCP2 expression with DRP1 expression, in order to clarify the 
role of mitochondria biogenesis in the etiopathogenesis of thyroid cancer, and specifically 
in Hürthle cells tumours. Our hypothesis is that UCP2 is an important regulator of DRP1 
expression in thyroid cancer, and that this regulation may be even more expressive in 
Hürthle cells tumours. 
 Our results indicate that UCP2 and DRP1 exhibit a higher expression in Hürthle cell 
tumors when compared to non-Hürthle cell tumors. In addition, we observed a significantly 
positive correlation between the expression of both mitochondrial proteins in Hürthle and 
non-Hürthle cell tumors, suggesting that DRP1 expression is regulated by UCP2 in both 
phenotypes. Although UCP2 did not seem to associate with any clinical-pathological 
characteristics of poor prognosis, it was negatively correlated with the presence of distant 
metastases. 
 Our findings suggest a role for UCP2 in the regulation of DRP1 expression in Hürthle 
and non-Hürthle cell tumors. The negative association between UCP2 and DRP1 
expression and the presence of distant metastases and the positive association between 
DRP1 expression and thyroid capsule invasion may indicate that UCP2, along with DRP1, 
are no longer as relevant for the generalization of the disease as they are in the earlier 
stages of progression and invasion. Weather this apparent pro-metastatic switch represents 
an adaptive metabolic mechanism associated to already well described molecular factors 
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and/or to the standard of care treatment of thyroid cancer with TSH suppression and iodine 
treatment, is something that warrants further investigation. 
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Resumo 
 Os tumores de células de Hürthle correspondem a um grupo particular de tumores 
da glândula da tireoide compostos exclusivamente, ou predominantemente, por células 
Hürthle ou oncocíticas, caracterizadas pelo seu consistente e elevado número de 
mitocôndrias, estrutural e funcionalmente aberrantes. O nosso grupo descreveu 
recentemente um aumento generalizado de proteínas envolvidas na morfologia e dinâmica 
mitocondrial em tumores de células de Hürthle, sugerindo um papel da alteração da 
biogénese mitocondrial normal na transformação oncocítica das células. Destas proteínas, 
a DRP1, uma proteína da família das dinaminas GTPases fulcral para a fissão mitocondrial, 
parece ser uma das mais sobre expressas nos tumores de células de Hürthle, padrão que 
foi igualmente descrito noutros tumores não oncocíticos. Num estudo recente foi 
demonstrado que a UCP2, membro de uma das maiores famílias de proteínas 
mitocondriais portadoras de aniões, e reguladora dos níveis de espécies reativas de 
oxigénio mitocondriais, regula o processo de fissão mitocondrial, através da regulação da 
expressão da DRP1. 
 No presente estudo, pretendemos avaliar a expressão da UCP2 e DRP1, por 
análise de imuno-histoquímica, numa série alargada de 245 carcinomas da tiróide, com e 
sem células de Hürthle, e correlacionar a expressão de UCP2 com a expressão de DRP1, 
de modo a esclarecer o papel da biogénese mitocondrial na etiopatogénese do cancro de 
tiróide e, especificamente, nos tumores de células de Hürthle. A nossa hipótese é a de que 
a UCP2 corresponde a um importante regulador da expressão da DRP1 em carcinoma da 
tiróide, e que essa regulação pode ser ainda mais expressiva nos tumores de células de 
Hürthle. 
 Os nossos resultados indicam que as proteínas UCP2 e DRP1 apresentam maior 
expressão nos tumores de células Hürthle quando comparados com tumores de células 
não-Hürthle. Adicionalmente, observámos uma correlação significativamente positiva entre 
a expressão das duas proteínas mitocondriais nos tumores de células Hürthle e de células 
não-Hürthle, sugerindo que a expressão de DRP1 é regulada pela UCP2 em ambos os 
fenótipos. Embora não tenhamos verificado qualquer associação entre a expressão da 
UCP2 e características clínico-patológicas de mau prognóstico, a expressão de UCP2 
associou-se negativamente com a presença de metástases à distância. 
 Os nossos resultados sugerem que a UCP2 tem um papel na regulação da 
expressão da DRP1 nos tumores de células Hürthle e não-Hürthle. A associação negativa 
entre a expressão das duas proteínas e a presença de metástases à distância, bem como 
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a associação positiva entre a expressão de DRP1 e a invasão de cápsula da tiróide, podem 
indicar que a UCP2, a par da DRP1, possa ser menos relevante para a generalização da 
doença, e mais importantes nos estádios iniciais de progressão e invasão tumorais. Se 
esta mudança pró-metastática representa um mecanismo de adaptação metabólica 
associada a fatores moleculares já bem descritos e/ou ao tratamento padrão do cancro da 
tiróide com iodo radioativo e supressão da hormona TSH, é algo que deve ser alvo de mais 
investigação. 
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1. Introduction 
1.1. Thyroid cancer: epidemiology, incidence and classification 
 Thyroid cancer (TC) is the most common endocrine malignancy representing less 
than 1% of all human cancers, and includes diseases with remarkably different features that 
vary from indolent localized papillary carcinoma to the lethal anaplastic cancer (1, 2). 
 TC’s incidence has continuously increased in the last decades worldwide (3), 
predominantly attributable to an increase in papillary carcinomas, while the incidences of 
the less common histological categories have remained relatively stable (4). This tumor type 
shift appears to be coincident with the extensive use of diagnostic sensitive techniques such 
as high-resolution ultrasound imaging and fine needle aspiration cytology (FNAC), 
improving the detection of small papillary carcinomas (4). The number of new cases of TC 
is estimated to range from 6.3 to 13.5 per 100,000 men and women per year, and the 
number of deaths ranged from 0.5 to 0.6 per 100,000 men and women per year in United 
States of America (5) and Europe (6), respectively. In 2017, it is estimated that there will be 
56,870 new cases of TC and an estimated 2,010 people will die from this disease (5). 
Although the mortality from TC has decreased over the years, the rate of disease recurrence 
remains elevated (7).  
 
 Approximately 60 to 80% of thyroid carcinomas detected nowadays are 
micropapillary thyroid carcinoma (<1 cm in size), with an excellent long-term prognosis (4). 
However, sensitive diagnostic procedures cannot entirely explain the increased in incidence 
of papillary thyroid cancer as the tendency is observed in both genders, among all ages, 
Figure 1 - Number of new cases and deaths (age-adjusted) per 100,000 (both sexes) in 
United States. Reused from SEER Stat Facts program (5), public domain. 
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tumor sizes, and different racial and ethnic groups. Other factors such as environmental 
influence, iodine intake, the Chernobyl disaster, use of medical radiation and ethnic and 
genetic factors, or a combination of these factors should be considered (8). 
 Histopathological classification of thyroid tumors is crucial for optimal patient 
management and for determining the clinical course of the disease. TC is classified in line 
with the cell type they derive from, degree of differentiation and cytoarchitecture. Tumors 
with follicular thyroid cell origin include papillary thyroid cancer (PTC), follicular thyroid 
cancer (FTC), poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer 
(ATC). PTC and FTC are classified as differentiated thyroid cancer (DTC), which comprises 
the clear majority (>90%) of all TCs (2, 9). A specific sub-phenotype of DTCs are Hürthle 
cell carcinomas (HCC), which are relatively rare cancer, accounting for only 3% of all DTCs 
(1). Medullary thyroid cancer (MTC) arises from the parafollicular cells or C cells and 
represents a rare malignancy, accounting for 3 to 10% of all TC (2). The main molecular 
mechanism implicit in MTC tumorigenesis is the aberrant activation of RET signaling, 
caused by RET mutations, which are not present in follicular thyroid cell-derived tumors 
(10).  
 It has been argued that TC prognosis depends more from the interplay between 
clinical and biological factors including age, gender, histopathological features – tumor size, 
morphological subtype, degree of differentiation, extension of necrosis, metastasis and 
signs of local and vascular invasion – and genetic factors, than from genetic factors alone 
(11-13).  
 Staging is recognized as the most important prognostic factor in TC (11). Several 
staging systems have been proposed to predict outcome, the most frequently used being 
the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer 
(UICC) TNM staging system based mostly on the extent of tumour and age (11, 14). Table 
1 presents the AJCC TNM staging system for DTC. The staging system can estimate high 
or minimal risk of cancer mortality. However, it is not able to predict the risk of recurrence. 
Therefore, the risk of disease recurrence is defined by the American Thyroid Association 
(ATA) on a 3-level of risk and is stratified as low, intermediate or high based on surgical 
pathology information (9). 
 Although TC is more common in women than man, at a ratio of 3:1 (6), mortality 
rates are higher among men than women (11), with gender being also an important 
prognostic factor. Age at diagnosis is a well-known prognostic factor in many different 
malignancies, including DTC. Indeed, mortality rate at the time of diagnosis is low for 
patients below the age of 45 and increases progressively after the age of 45. In this way, 
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patients older than 45 at diagnosis carry a guarded prognosis for survival and are more 
likely to develop locally aggressive tumors and have clinical recurrence (11). This cut-off 
value — 45 — is one of the major determinants used in the UICC/AJCC staging system 
(14).  
 
Table 1 - AJCC/UICC TNM staging system for DTC 
Adapted from UICC/AJCC TNM 7th edition 2010 (14) 
 Stage < 45 years old Stage ≥ 45 years old 
Stage I Any T, any N, M0 T1, N0, M0 
Stage II Any T, any N, M1 T2, N0, M0 
Stage III - 
T3, N0, M0 
T1, N1a, M0 
T2, N1a, M0 
T3, N1a, M0 
Stage IVA - 
T4a, N0, M0 
T4a, N1a, M0 
T1, N1b, M0 
T2, N1b, M0 
T3, N1b, M0 
T4a, N1b, M0 
Stage IVB - T4b, Any N, M0 
Stage IVC - Any T, any N, M1 
  
 Although the controversy about whether lobectomy alone is sufficient therapy for TC 
or if total thyroidectomy is necessary, surgery is the mainstay of treatment for TC (15). It 
was demonstrated that patients with larger tumors (> 1 cm) have a higher rate of cancer 
death with lobectomy compared with total thyroidectomy (16) wherefore the extent of 
thyroidectomy has major prognostic implications. Follicular cell-derived tumor treatment 
comprises radioactive iodine (RAI) and thyroid suppressive hormone (TSH) therapies, 
which are often effective. Surgery is usually followed by RAI through 131I administration 
which has been recognized to be the most effective adjuvant treatment since the radiation 
is able to destroy thyroid cells, including cancer cells that take up iodine, being able to 
eliminate any residual microscopic foci of diseases, and to detect recurrent or metastatic 
disease (17). In TC, most of local recurrences that develop are detected in the first 5 years 
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after diagnosis wherefore follow-up is vital to detect recurrent or persistent locoregional 
disease, or distant metastases.(4).  
 Four different gene mutations with significant effects on tumor prognosis and 
diagnosis have been identified: BRAF and RAS point mutations, and RET/PTC and 
PAX8/PPARγ rearrangements (18). The most common genetic changes in PTC include 
point mutations of BRAF which are observed in 36–83% of the cases (13). These mutations 
lead to the constitutive activation of BRAF kinase and stimulation of the mitogen-activated 
protein kinase (MAPK) signaling pathway, which is responsible for thyroid tumorigenesis 
(18). BRAF mutation has been associated with poor prognostic indicators like older age, 
male gender, extrathyroidal invasion, tumor recurrence and higher tumor staging. However, 
other studies did not found such association with signs of clinical-pathological 
aggressiveness, which imply that the putative role of the BRAF mutation remains unclear 
(13, 18). Indeed, in PTC, BRAF mutation is present in about 50% of tumors from which less 
than 10-15% will exhibit aggressive behavior (11). Our group detected TERT promoter 
mutations in PTC, FTC, PDTC and ATC, and these were found to be associated with older 
age, larger tumors and presence of metastases in DTC, which suggest that such mutations 
may constitute a molecular marker for prognostic  (19). Finally, mutations of TP53 have 
been widely described in PDTC and ATC, but this mutation has also been described 
recently in DTC. Histologic characteristics of aggressiveness support the fact that TP53 
inactivation plays a role in the progression of differentiated to undifferentiated tumors (14). 
 HCC may have a distinct molecular profile compared to other DTCs, since HCC 
does not harbor classical genetic alterations, such as BRAF and RAS mutations or 
RET/PTC rearrangements. 
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1.2. Differentiated Thyroid Cancer 
 
1.2.1. Papillary Thyroid Cancer 
 The most frequent type of TC is PTC, accounting for 75–85% of all cases (3). 
Papillary carcinoma is defined as a “malignant epithelial tumor showing evidence of follicular 
cell differentiation, and characterized by distinctive nuclear features”, with nuclear features 
being the key to diagnosis (2). PTC are frequently infiltrative but some may be encapsulated 
(2). There are several histopathological subtypes of PTC based on the architectural features 
of the tumor: classical, follicular, tall-cell, columnar-cell, cribriform-cell, Hürthle cell, diffuse 
sclerosing and solid variants (18). Previous irradiation of the head and neck region, 
exposure to radiation, positive family history or Hashimoto thyroiditis are risk factors for PTC 
(20). PTC shows a propensity to invade locally and to metastasize to regional lymph nodes, 
whereas distant metastases by hematogenous spreading is relatively uncommon (9%-14%) 
and generally occurs late in the course of the disease (17). The overall 5 and 10-year 
survival rates of PTC are approximately 97% and 93%, respectively (3). 
 Three mutually exclusive molecular alterations are recognized in PTC: point 
mutations of BRAF and RAS genes and RET/PTC rearrangements (10, 18). Among the 
various prognostic factors for PTC, the most important are age, tumor size and stage (21). 
In patients with PTC the tumor size correlates with their outcome, as the risk of recurrent 
disease and cancer-specific mortality increases with tumor size, and larger tumors are more 
likely to present locoregional and distant metastases (22). Furthermore, microscopic 
extracapsular extension and invasion of the tumor outside the capsule are associated with 
a higher risk of recurrent disease (12). 
 
1.2.2. Follicular thyroid cancer 
 The World Health Organization (WHO) defined FTC as a malignant epithelial tumor 
showing follicular cell differentiation and lacking the diagnostic nuclear features of PTC (2). 
FTC is the second most common thyroid malignancy, accounting for 10–15% of TCs (3). In 
contrast to PTC, metastases to distant organs are common in patients with FTC (23). In this 
way, prognosis of FTC is worse than PTC notably in patients with distant metastases where 
the outcome is often poorer. The overall 5 and 10-year survival rates for FTC are 91% and 
85%, respectively (9). 
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 Multifocality in FTC is uncommon and most FTCs are well-encapsulated solid 
tumors characterized by capsular and/or vascular invasion at diagnosis (24). Approximately 
50% of FTC patients have mutations in RAS genes or PAX-PPAR rearrangements (10). 
 
1.2.3. Hürthle cell tumors  
 First described by Ewing in 1928 (25), Hürthle cell tumors only represent about 3% 
of all TC (1). They are defined as encapsulated tumors composed of more than 75% of 
Hürthle cells and can be classified as Hürthle cell adenoma (HCA) and Hürthle cell 
carcinoma (HCC), based on their malignancy. Since the cytological features of HCC are 
indistinguishable from their benign counterparts, its malignancy cannot be diagnosed 
without the identification of capsular and/or vascular invasion, these being the hallmark 
findings of HCC (26, 27).  
 Additionally, HCC may be categorized as minimally invasive or widely invasive, 
according to the presence and degree of vascular and capsular invasion (24). Clinically, 
widely invasive HCC are more likely to metastasize into the lymphatics of the neck and 
distant sites, such as lung, liver and bone, than into cervical lymph nodes, are more iodine 
resistant, and have higher mortality than other DTCs. In contrast, minimally invasive 
carcinoma should be regarded as low grade, appears to have a benign behavior and may 
benefit from a less aggressive therapeutic approach (28). Therefore, patients with the widely 
invasive form of HCC have a poor prognosis with a recurrence rate of 31% and disease-
specific mortality rate of 25%, whereas the mortality rate is higher when patients present 
distant metastases (80%) (26).  
 The so-called Hürthle cells, alias oncocytic-, alias oxyphilic-, alias eosinophilic-cells 
are large polygonal cells with distinct borders derived from thyroid follicular epithelium that 
has been damaged. These cells are characterized by the cytoplasmic accumulation of 
abundant mitochondria that frequently display abnormal morphology (29).  
 Hürthle cell changes are common in various thyroid conditions, including non-
neoplastic pathology such as Hashimoto’s thyroiditis, Grave’s disease and nodular goiter 
(27, 29). Hürthle cell transformation occurs in other endocrine organs, salivary glands, 
kidney and other parenchymatous organs, suggesting that this alteration occurs in tumors 
with low proliferative index and reduced turnover, allowing the accumulation of abnormal 
mitochondria, which describe Hürthle cells (30). There are Hürthle cell variants of PTC, 
FTC, PDTC and MTC (29). ATC is the only exception, probably because the neoplastic 
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cells divide too often to allow the accumulation of mitochondria that characterize Hürthle 
cells (29). 
 HCC is defined as an oncocytic variant of FTC according to the WHO (2). This would 
imply that HCC carry similar genetic abnormalities to those of FTC, yet HCC have a different 
molecular profile, suggesting that FTC and HCC should be recognized as two separate 
entities, regardless the common origin in the follicular cell (26). Indeed, Ganly et al., found 
through a detailed analysis a series of recurrent deletions/amplifications in different 
chromosomes, indicating chromosome instability in HCC. This level of chromosome 
instability is notable when compared with other non-oncocytic DTCs, and may contribute to 
explain the aberrant mitochondrial hyperplasia that is associated to the occurrence of 
pathogenic mitochondrial DNA (mtDNA) mutations (26). Additionally, it was expected that 
RAS mutations, one of the main genetic alterations in FTC, were present in HCC with the 
same frequency. However, the authors reported that only 11% of HCC present RAS 
mutation. The authors also confirmed  that the two most common genetic alterations in PTC, 
BRAF mutation and chromosomal RET rearrangements, were not present in HCC (26). 
Similarly, a recent study also demonstrated that BRAF, RAS, RET/PTC oncogenic events 
are rare in HCC (31). Likewise, the frequency of TERT promoter mutations is lower in 
tumors with oncocytic features than in their non-oncocytic counterparts, suggesting once 
again that oncocytic tumors have a distinct molecular profile (13). 
 Although some divergence among pathologists, it is generally accepted that HCCs 
are more aggressive, with a higher rate of locoregional recurrence, distant metastases and 
mortality compared to FTC (15). Some studies reported poor outcomes, with an overall 
survival rate of 64% in HCC and 79% in FTC. Conversely, other studies demonstrated 
contradictory results indicating that HCC is no more aggressive than FTC (32, 33). Indeed, 
a 35-year follow-up study reported that survival in HCC has improved significantly over the 
years and patients with HCC had a similar overall survival compared to those with FTC (33). 
These controversial findings in HCC survival may be explained by better detection, 
improved treatment and follow-up, or a fundamental change in the biology of the disease 
(33).   
 From a clinical standpoint, the negative characteristic of HCCs is that they are less 
RAI avid due to their lesser ability to trap iodine (30). Consequently, HCC need a more 
aggressive approach to the treatment. 
 Since HCC is a rare disease, the clinical behavior and prognostic indicators of 
outcome remain unclear. Therefore, it is important to identify molecular pathways that may 
be altered in these cancer cells allowing the identification of potential targets for new 
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therapeutic approaches. Recently, an overall increase in the levels of "mitochondria-
shaping" proteins in Hürthle cell tumors was described, suggesting a role for abnormal 
mitochondrial biogenesis in Hürthle cell transformation. From those proteins, dynamin-
related protein 1 (DRP1), a member of the dynamin family GTPases required for 
mitochondrial fission, appears to be one of the most overexpressed in Hürthle cells tumours 
(34). However, the mechanism by which DRP1 is overexpressed in Hürthle cell tumors is 
still unclear. 
 
1.3. Mitochondrial dynamics 
 A remarkable feature of cancer metabolism was described by Otto Warburg, who 
found that cancer cells undergo a shift in their basal metabolic pathways, producing most 
of their ATP by glycolysis - the “Warburg effect” (35) -, which is followed by a change in 
mitochondrial morphology and size (36), dependent on the balance between mitochondrial 
fusion and fission (37). 
 Mitochondria are highly dynamic and functionally versatile organelles, constantly 
changing their morphology and size in response to different physiological needs of the cell 
through biogenesis and degradation. These organelles move along the cytoskeleton 
through microtubules to accomplish their functions and are accumulated at sites where 
elevated amounts of energy are needed (38-40). Therefore, it is important to understand 
the complex molecular machinery regulating mitochondrial dynamics. 
 The shape of the mitochondrial network results from the cumulative activity of two 
opposing processes – fusion and fission – that ensure homeostatic maintenance of different 
cellular functions, such as generation of reactive oxygen species (ROS), neuronal plasticity 
and muscle atrophy, cellular bioenergetics, commitment to mitosis and also apoptosis (40). 
Thereby, defects in the regulation of mitochondrial dynamics are linked to human 
pathologies, including cancer, cardiovascular and neurodegenerative diseases (41-43). 
Indeed, unbalanced mitochondrial fusion and fission has been proposed to contribute to 
tumorigenesis by influencing mitochondrial functions, and interfering with synthesis of DNA 
and protein, apoptosis, autophagy and ROS production (39).  
 Mitochondrial fusion and fission are highly conserved processes, orchestrated by 
dynamin related GTPases. Fusion is mediated by the inner membrane protein optic atrophy 
1 (OPA1) and the outer membrane proteins mitofusins (MFN) 1 and 2, whereas fission is 
mediated by dynamin-related protein 1 (DRP1), a large cytosolic guanosine-5-
triphosphatase as represented in Figure 2. The fusion proteins hydrolyze GTP to fuse two 
 
 
 
11 
 
adjacent mitochondria together to allow sharing of mtDNA, proteins and metabolites (40, 
44).  
1.3.1. Mitochondrial fission 
 Mitochondrial fission comprises the division of one mitochondrion into two or more 
mitochondria (44). This process ensures equal division of mitochondrial numbers to the 
daughter cells during cell division, mediates the selective removal of abnormal mitochondria 
through a quality process called mitophagy, thereby maintaining a healthy mitochondrial 
network, and promotes apoptotic cell death (40, 45, 46). Mitochondrial division is also 
needed in quiescent cells, during cellular differentiation, cell growth or in response to 
extracellular stimuli (40, 44).  
 In mammals, the major player in mitochondrial fission is the large member of the 
dynamin family of GTPases, DRP1, that is known to constrict and tabulate membranes (37, 
44, 47). DRP1 is translocated from cytosol to mitochondria and promote mitochondrial 
division after undergoing extensive post-translational modifications (44), specifically 
phosphorylation (48, 49). S-nitrosylation (50), ubiquitination (51) and SUMOylation (52) are 
other post-translational modifications which alter both its localization and affinity for 
oligomerization (37). DRP1 oligomerizes into spirals around the mitochondrial outer 
membrane (MOM), which constricts the organelle through GTP hydrolysis until the lipid 
bilayers are sufficiently destabilized to break apart from each other promoting mitochondrial 
fragmentation (37, 53). DRP1 then reverts to its monomeric structure and returns to the 
cytosol, leaving two mitochondria behind (54). This process is reached through the 
interaction of DRP1 with other proteins of the fission machinery including mitochondrial 
fission factor (MFF), human fission protein 1 (FIS1) and mitochondrial dynamics proteins of 
49 (MiD49) and 51 kDa (MiD51) at the MOM, as represented in Figure 2 (53). 
 The most widely reported DRP1 post-translational modification is phosphorylation, 
which occurs at Ser616 and Ser637 residues by cyclin-dependent kinase 1 (Cdk1)/cyclin B 
and cAMP-dependent protein kinase (PKA), respectively. Phosphorylation of S616 by 
Cdk1/cyclin B promotes DRP1 translocation to the mitochondria and therefore induces 
mitochondrial fission during mitosis where it ensures an equal division of the mitochondrial 
network between daughter cells (48). In contrast, phosphorylation at the other site, Ser637, 
by PKA has an opposing effect, inactivating GTPase activity of DRP1 which suppresses 
mitochondrial fission and prevents cell death (55). Conversely, dephosphorylation of S637 
by the Ca2+-dependent phosphatase calcineurin promotes mitochondrial fission through 
DRP1 recruitment to the mitochondria, and is involved in the initiation of apoptosis (56, 57). 
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1.3.2. DRP1-mediated mitochondrial fission in cancer 
 Cumulative evidence has been suggesting a link between dysregulated 
mitochondrial dynamics and cancer. Indeed, high expression or enhanced activation of 
DRP1 and/or downregulation of MFN2, mediate this phenotype in TC (34), lung cancer (58), 
metastatic breast cancer (59), glioblastoma (60), colorectal cancer cells (61), pancreatic 
cells (62) and melanoma (63, 64). Additionally, mitochondrial dynamics have been 
associated with cell malignant activity, such as migration and invasion in breast cancer, TC 
and glioblastoma cells (34, 59, 60). In lung adenocarcinoma cells, it was demonstrated that 
decreased fusion and increased fission leads to disruption of the mitochondrial network. 
(58). Furthermore, the authors reported elevated levels of the activated form Ser-616-
phosphyralted DRP1, and lower levels of the inhibited form Ser-637-phosphorylated DRP1, 
enhancing the active form of DRP1. Conversely, DRP1 inhibition and MFN2 overexpression 
was shown to promote cell cycle arrest and increase apoptosis in lung adenocarcinoma cell 
lines (58). These events have also been verified in vitro and in vivo in other cancer models, 
including colon, breast and cervical cancer cells (61, 65, 66). It has been suggested that 
mitochondrial dynamics has a key role in metastization (59). Overexpression of DRP1 was 
observed in human invasive and metastatic breast cancer, whereas DRP1 silencing was 
shown to inhibit invasion and migration (59). This pattern of dysregulated mitochondrial 
fission has also been observed in melanoma, where it was found that ERK-mediated 
Figure 2 – Mitochondrial dynamics in mammalian cells. A – Mitochondrial fusion consist 
in the fusion of the outer membrane (OM) of two mitochondria regulated by MFN1 and 
MFN2, followed by the fusion of inner membranes (IM) regulated by OPA1; B – 
Mitochondrial fission consists in the division of one mitochondrion into two or more 
mitochondria. DRP1 is recruited from the cytosol to the MOM where it interacts with other 
proteins of the fission machinery including MFF, FIS1, MiD49 and MiD51. Reused with 
permission from Mishra, P. and Chan, D. (2014) (42) 
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phosphorylation of DRP1 promotes fission which is essential for Ras-mediated 
transformation and mitochondrial reprogramming (63). It has also been verified that DRP1-
mediated mitochondrial fission is enhanced by the overexpression of the oncogenic protein 
survivin, contributing to the development of a glycolytic phenotype in neuroblastoma (67). 
Therefore, mitochondrial fission may represent a therapeutic target for cancers that present 
such an excessive process (62, 63). 
 Recently, an overall increase in the expression levels of "mitochondria-shaping" 
proteins in Hürthle cell tumours was described, suggesting a role for abnormal mitochondrial 
biogenesis in Hürthle cell transformation (34). From those proteins, DRP1 appears to be 
one of the most highly expressed in Hürthle cells tumours (34).However, the mechanism by 
which DRP1 is overexpressed in Hürthle cells is not yet known. 
 A recent study has demonstrated that UCP2, a key modulator of mitochondrial ROS, 
controls mitochondrial fission process through DRP1 expression regulation (68). Previously, 
it was reported that mitochondrial changes in arcuate neurons were promoted by UCP2 (69, 
70). Similarly, Toda et al.., also reported mitochondrial changes, such as increase in 
mitochondrial density and reduction in mitochondrial size, in ventromedial nucleus of the 
hypothalamus (VMH) neurons mediated by UCP2, suggesting that UCP2 is involved in the 
regulation of mitochondrial fission process. In this way, the authors assessed the effect of 
UCP2 in DRP1, the major regulator of mitochondrial fission process, to understand whether 
the presence of UCP2 impacts on DRP1 phosphorylation, and subsequent activation, in 
response to a glucose load. They verified a significant increased ratio of pDRP1/DRP1 in 
UCP2 knockout (UCP2KO) mice with selective re-expression of UCP2, and in mice with 
selective overexpression of UCP2 in SF1 neurons when compared to control mice. These 
results indicate that UCP2 is important for DRP1 phosphorylation in the VMH in response 
to glucose load and may have a key role in the regulation of mitochondrial fission (68). 
Interestingly, a few years ago UCP2 was found to be overexpressed in Hürthle cell tumours 
(71). 
 
1.4. Mitochondria: the primary source for cellular functions 
 Mitochondria are known as the powerhouses of eukaryotic cells due to their ability 
to couple oxidation of nutritional substrates with high-yield ATP production, process 
denominated oxidative phosphorylation (OXPHOS) (72). In addition, mitochondria integrate 
several processes which are essential for cell survival and function such as modulation of 
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oxygen concentration, ROS production, apoptotic and necrotic cell death, calcium and iron 
homeostasis and certain metabolic and biosynthetic pathways (73).  
 During OXPHOS, electrons derived from reduced substrates generated by the 
tricarboxylic acid (TCA) cycle or by β-oxidation of fatty acid are transported along series of 
carriers embedded in the inner mitochondrial membrane, which constitute the electron 
transport chain. The energy released from electron transport is used to drive the synthesis 
of ATP from ADP for active pumping of protons across the inner membrane, generating an 
electrochemical gradient (74). Finally, the molecular oxygen is reduced at complex IV 
(cytochrome oxidase) whereas the energy, conserved as a proton gradient, is used by F0F1 
ATP synthase to generate ATP as protons are transported back from the intermembrane 
space into the mitochondrial matrix (75). However, the conversion of substrate energy into 
ATP is not a fully efficient process since some of the energy generated in the 
electrochemical gradient is not coupled to ATP synthesis and may be lost as heat. This 
process can be associated to the consumption of energy via proton leak reactions, which 
consists of the return of protons to the mitochondrial matrix bypassing the ATP synthase 
(76, 77). Although some inefficiency may be attributed to intrinsic biophysical properties of 
the inner membrane, this proton conductance is mostly associated to mitochondrial inner-
membrane proteins termed uncoupling proteins (UCP) as represented in Figure 3 (75-77). 
This nonproductive proton leak is physiologically vital and accounts for 20-25% of the basal 
metabolic rate (77). UCPs are mitochondrial anion transporter proteins encoded by nuclear 
DNA and localized into the mitochondrial inner membrane (78). These proteins uncouple 
the OXPHOS from ATP production by dissipating the proton gradient, regulate transport of 
anions across the mitochondrial inner membrane, decrease the generation of ROS and the 
levels of calcium in the mitochondrial matrix (75, 77, 78).  
 Thus far, five UCP family members have been identified in mammals (75, 79). The 
best well characterized is UCP1, which is highly expressed in brown adipose tissue with a 
key function in adaptive non-shivering thermogenesis, by dissipating the electron-proton 
gradient in the form of heat (73, 80). UCP1-mediated proton leak is activated by fatty acids 
in response to cold exposure and β-adrenergic stimulation, and has a crucial role for 
hibernating and newborn animals (81).  
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 UCP2 and UCP3 shares 59% and 57% of amino acids sequence identity, 
respectively, with UCP1, and 73% identity with each other. Compared with UCP1, the 
biological role of these proteins is not well-known (77). UCP2 is widely distributed 
throughout the organism, whereas UCP3 is mainly restricted to skeletal muscle and might 
play a significant role in attenuation of ROS production and fatty acid metabolism (75, 82). 
Due to his ubiquitous distribution, UCP2 has a role in numerous metabolic mechanisms and 
its misregulation is associated to pathologic events, including cancer (77). Yet, the 
abundance of UCP2 and UCP3 is much lower than levels of UCP1 found in adipose tissue, 
suggesting that UCP2 and UCP3 are not the major modulators of energy balance under 
normal conditions (76). Moreover, UCP2 and UCP3 have been suggested to maintain a 
normal membrane potential whenever there an excessive amount of ROS production, yet 
with an undetectable effect on metabolic rate, suggesting that UCPs have an antioxidant 
effect preventing oxidative injury (75). The other two members, UCP4 and UCP5, are mainly 
expressed in the central nervous system and have a low sequence identity with UCP1 (73). 
It has been demonstrated that these two uncoupling proteins protect neurons from an 
excessive production of ROS reducing the mitochondrial membrane potential (73).  
 
 
Figure 3- Mitochondrial oxidative phosphorylation system and uncoupling protein. 
Reused with permission from Baffy, G. (2010) (81) 
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1.4.1. Expression of UCP2: tissue distribution and physiological role 
 UCP2 is present in numerous tissues including thyroid, brain, pancreas, liver, 
immune cells, adipose tissue, kidney, spleen, testis, muscle, heart, thymus, lung and the 
central nervous system (71, 77, 78, 82-84). This mitochondrial protein has been associated 
with several physiological events such as inflammation (85), insulin production (81), 
immunity (86), lipid metabolism (87), aging (78) and inhibition of apoptosis (88), and has 
been involved in pathological mechanisms of neurodegenerative disorders (89), 
carcinogenesis (76) and metabolic disorders, such as obesity and diabetes (87). While 
UCP2 seems to be not entirely involved in thermogenesis, it plays an important function in 
the control of the production of mitochondrial ROS, promoting a negative feedback to control 
mitochondrial oxidative stress (77). Its widespread expression among organs is consistent 
with a wide variety of physiological roles, indicating that UCP2 is a physiologically important 
protein, and thus UCP2 may represent an attractive therapeutic target. 
 
1.4.2. UCP2: ATP and mitochondrial ROS generation 
 During the last decades, the main function of UCP2 has been thought to be the 
mediation of proton leak (76, 77). Indeed, UCP2-induced proton leak confers more benefit 
to the cells than the OXPHOS, since UCP2 may be utilized to regulate metabolic signals 
and pathways via control of ATP production, oxidative stress via control of ROS production 
and intracellular oxygen distribution via control of mitochondrial respiratory rate (76). 
Furthermore, previous research has documented that UCP2, as member of UCP 
superfamily, uncouples the respiratory chain from mitochondrial ATP synthase in 
mammalian cells (76). However, its status as functional UCP is in doubt by many authors 
and there has been some disagreement regarding whether UCP2 is able to uncouple at all 
(76, 77). Consequently, many years after its identification, many hypothesis regarding 
UCP2 appeared to be unfounded about whether an increase in UCP2 per se induces 
mitochondrial uncoupling and affects ATP generation (76). Derdak et al.. demonstrated that 
ATP levels remains unchanged in HCT116 cells with and without UCP2 overexpression, 
which may suggest that the impact on energy homeostasis depend on the amount of ectopic 
UCP2 and its effect in cellular energy balance may be negligible (90).  
 In the light of recent studies in UCP2, some of the differing observations may be 
explained by the low levels of UCP2 found in mitochondria, which difficult the detection of 
its uncoupling activity and UCP2 need to be activated to exhibit its uncoupling activity. 
Additionally, some divergences found in studies achieved with isolated mitochondria and 
with living cells can be elucidated by the fact that the proton transport activity of UCP2 in 
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isolated mitochondria could not be demonstrated (77). Therefore, further research is 
necessary to extend our knowledge of the uncoupling role of UCP2.  
 The mitochondrial electron transport chain is an inherent source of intracellular 
ROS. Although transported electrons are destined to reach molecular oxygen at the level 
of cytochrome oxidase, some electrons may escape the electron transport chain at previous 
steps and partially reduce the molecular oxygen into superoxide, a process that arises at 
higher mitochondrial membrane potential values (91). Since superoxide production is very 
sensitive to changes in mitochondrial membrane potential, lowering of mitochondrial 
membrane potential by proton leak will predictably diminish mitochondrial superoxide 
production (76). Thus, UCP2 activity can be regulated by superoxide, the primary 
mitochondrial form of ROS (92), at post-translational level, which increases the activity of 
UCP2. Additionally, UCP2-mediated proton leak can also be regulated by lipid peroxidation 
derivatives (93). 
 The accumulating evidence suggests that the main physiological role of UCP2 is to 
lower the production of ROS, rather than participating in energy expenditure or metabolic 
control (91). UCP2 regulates not only mitochondrial ATP production, but also the generation 
of ROS (77). The transport of protons from the intermembrane space to the mitochondrial 
matrix by UCP2 bypassing ATP synthase generates a decrease of mitochondrial membrane 
potential and superoxide ion production into mitochondrial matrix, providing an antioxidant 
effect to UCP2, and accelerates the flow of electrons along the respiratory chain, which 
results in higher rates of mitochondrial substrate oxidation and oxygen consumption (76, 
82). Consistently, it has been demonstrated that a small decrease of mitochondrial 
membrane potential termed mild uncoupling has a natural protective effect. Indeed, ROS 
production is more sensitive to uncoupling-induced membrane potential changes than ATP 
synthesis, further suggesting that mild uncoupling has more benefit than harm, in which 
UCP2 contribute to this protective mechanism (76). Thus, suppression of mitochondrial 
ROS by uncoupling of oxidative phosphorylation can represent the first line of antioxidant 
defense against oxidative stress, and subsequently, overexpression of UCP2 prevents 
oxidative injury (76, 82).  
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1.4.3. Role of UCP2 in tumorigenesis 
 Various approaches have been put forward and have well established the key role 
of UCP2 in both tumorigenesis and chemoresistance. UCP2 expression in cancer cells is 
not only a marker of oxidative stress, but it may also contribute to the selection of cancer 
cells with enhanced adaptive abilities (76). The accepted hypothesis proposes that, in the 
tumor initiation phase, down-regulation of UCP2 improves oxidative stress through ROS 
increase, whereas overexpression of UCP2 in the next stages of cancer development and 
attenuation of ROS production protects the cells from apoptosis and reduces their sensitivity 
to damaging agents, determining chemoresistance (94, 95). Indeed, UCP2 overexpression 
in cancer cells may lead to the inhibition of the pro-apoptotic p53 translocation to 
mitochondria by the dissipation of the mitochondrial potential, helping cancer cells to escape 
from p53-mediated apoptosis (77, 82). The dual regulation of UCP2 expression in the 
distinct stages of cancer development has been verified in various cancer cells: breast 
cancer cells where UCP2 inhibition promotes an increase in mitochondrial potential 
membrane, ROS production and apoptosis (96), drug-resistant sub-lines of leukemia and 
melanoma cells which display increased levels of UCP2, lower membrane potential and 
less predisposition to cytotoxic effects (97), and drug-resistant colon cancer cells in which 
overexpression of UCP2 inhibits ROS accumulation and apoptosis after exposure to 
chemotherapeutic agents (90). These findings indicate that UCP2 has a protective role in 
cancer cells whereas its overexpression confers resistance to chemotherapy and a higher 
survival through downregulation of ROS production. 
 In cancer cells, mitochondrial functions are adapted to meet the distinct needs and 
accountabilities of rapid and uncontrolled proliferation (98). Coexistence of the Warburg 
effect and increased UCP2 expression in cancer cells has been previously described, 
suggesting that UCP2 leads to the glycolytic phenotype (99). As reported by Xu et al.. (100), 
UCP2 sustains the shift from OXHOS to aerobic glycolysis, as a metabolic adaptation of 
cancer cells. Moreover, the high production of lactate after the overexpression of UCP2 
supports that UCP2 is involved in maintaining the Warburg effect in cancer cells (100). Also, 
the results obtained by Brandi et al.. (82) propose that UCP2 activates a variety of important 
metabolic enzymes/proteins in pancreas cancer cells, suggesting that UCP2 may promote 
the glycolytic phenotype. Specifically, they demonstrated that UCP2 induces the expression 
of the heterogeneous nuclear ribonucleoprotein A2/B1 (hnRMPA2/B1), which suggests its 
involvement in the up-regulation of the glucose transporter GLUT1 and the alternative 
splicing of the pyruvate kinase isoform M2 (PKM2), resulting in increased secretion of L-
lactic acid. Thus, these findings support the hypothesis that UCP2 regulates the cancer 
cellular bioenergetic shift to a glycolytic phenotype.  
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1.4.4. UCP2 expression in cancer 
 Several studies have found robust evidence that UCP2 has a role in supporting 
tumor growth. UCP2 expression appears to be increased in numerous cancers, including 
colon cancer (101), head, neck, skin, pancreas and prostate cancers (102), thyroid cancer 
(71), breast cancer and most other tumors (99). In breast cancer patients, higher UCP2 
expression correlated with poor prognosis (96). Horimoto et al.(103) reported increased 
UCP2 expression in human colon cancer, in which UCP2 is hardly detected in hyperplastic 
polyps (11%) and highly expressed in tubular adenomas (58.8%) and colon 
adenocarcinomas (86.0%). Berthiaume et al. (104), detected increased UCP2 expression 
in hepatocellular cancer (33.3%), and yet undetectable expression in normal liver 
specimens. In hepatocellular carcinoma, colon and breast cancer cells, knockdown or 
inhibition of UCP2 promoted apoptosis and increased sensitivity to anticancer drugs (96, 
105, 106), while its overexpression in colon cancer cells increased their resistance to 
chemotherapeutics in vitro and in mouse xenografts (90). Additionally, overexpression of 
UCP2 in breast cancer cells increased their tumorigenic phenotype, both in vitro and in vivo 
in a mouse xenograft model (99). However, contradictory results have shown that lung 
cancer cells expression of UCP2 was lower than in normal cells, and that its low expression 
was associated with chemotherapy resistance in lung cancer patients (107). Wherefore the 
exact role of UCP2 upregulation in cancer remains unclear. 
 In summary, tumor promotion, metabolic reprogramming, chemo-resistance, and 
redox regulation are some of the advantages of UCP2 overexpression in cancers. Targeting 
UCP2 could therefore serve as a potential therapeutic target for cancer prevention and 
therapy. 
 Association between carcinogenesis and UCPs are not limited to UCP2. Indeed, 
UCP1 expression was found to correlate with disease progression from primary to bone 
metastatic cancers in prostate cancer cell lines induced for osteoblastogenic and 
adipogenic differentiation (108). Increased UCP4 expression was a reliable marker of lymph 
node metastases in breast cancer (109). Additionally, overexpression of UCP4 was shown 
to inhibit apoptosis and promote cell proliferation in an ERK-dependent manner (110). 
Conversely, it was also demonstrated in neuronal differentiation studies using mouse stem 
cells that UCP4 expression levels are higher in differentiated nonproliferating cells, and that 
its expression in most cancer cell lines is low (111). Regarding UCP5, postmenopausal 
breast cancer that simultaneously displayed a low ER status and higher UCP5 expression 
had a worse prognosis (112). UCP3 is usually expressed in skeletal muscle and heart, and 
may play a similar role as UCP2 in several cancers, although the role of UCP2 is more well-
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studied and established. UCP3 expression is high in some cancers, including renal cell 
carcinoma (113). Interestingly, overexpression of UCP3 suppressed carcinogenesis in 
human and mouse keratinocytes (114, 115). Numerous studies have suggested that high 
UCP3 expression is associated with muscle wasting in tumor-induced cachexia (116-120). 
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2. Objectives 
 In this study, we intend to assess UCP2 expression in a larger series of DTC, with 
and without Hürthle cells, and to correlate its expression with DRP1 expression, to further 
clarify the role of mitochondria biogenesis in the etiopathogenesis of thyroid cancer, and 
specifically in Hürthle cells tumours. Our hypothesis is that UCP2 is an important regulator 
of DRP1 expression in DTC, and that this regulation may be even more expressive in 
Hürthle cells tumours. 
 
To achieve this objective, we will: 
1. Assess the expression of DRP1 and UCP2 based on a series of 245 follicular cell-
derived thyroid tumours, with and without Hürthle cells, - already described from a 
clinical, histopathological, genetic and molecular profile perspective; 
2. Correlate UCP2 expression with DRP1 expression; 
3. Define the association of DRP1 and UCP2 expression with the clinical-pathological 
features of the tumours, namely the presence and absence of Hürthle cells. 
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3. Material and methods 
3.1. Ethical conduct of the study 
 The study was performed in accordance with ethical principles that have their origin 
in the Declaration of Helsinki and are consistent with Good Clinical Practice, and applicable 
regulatory requirements Subject data protection. Furthermore, all collected data have been 
analysed and stored according to the legal requirements of Portuguese Law, thereby 
ensuring the privacy of individual subject’s data.  
3.2. Ethics and regulatory review 
 According to Portuguese Law, given the observational nature of the study, local 
Institutional Ethics Committee’s approval must be provided before implementing the 
Protocol. The material used in this study have come from the files of the Institute of 
Molecular Pathology and Immunology of the University of Porto (Porto, Portugal), 
corresponding to patients followed up in two university hospitals in Portugal, and from the 
clinical databases of these hospitals. To have access to these samples, researchers must 
submit a project to the Ethics Committee of each institution for approval. Our research 
project has been approved by Ethics Committee of each institution. 
3.3. Patient selection 
 A series of 245 formalin-fixed, paraffin-embeded tissue samples from follicular cell-
derived carcinomas were collected from the files of the Institute of Molecular Pathology and 
Immunology of the University of Porto (IPATIMUP), originated from patients followed in two 
university hospitals in Portugal. Clinical-pathological variables, including age, gender, 
histologic type, TNM stage, vascular invasion, multifocality, tumor capsule invasion, thyroid 
capsule invasion, extrathyroidal invasion, presence of BRAF mutation, follow-up time were 
obtained from histopathological reports and clinical databases. The histology of all tumors 
samples was revised independently by two pathologists (ER and MSS), and the final 
classification was made according to the WHO criteria (4).  
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3.4. Immunohistochemical analysis 
 Immunohistochemical analysis (IHC) was performed in 3 μm formalin-fixed, paraffin-
embedded sections. Sections were deparaffinized and rehydrated in a series of decreasing 
concentration of ethanol solutions. Deparaffinized single specimens were subject to heat-
induced antigen retrieval either in 10mM pH6 citrate buffer (sodium citrate) or in 1mM pH9 
ethylenediamine tetra acetic acid buffer (EDTA) (LabVision Corporation, Fremont, CA, 
USA), in a microwave set at 300 watts for 10 minutes. 
 After retrieval solutions had cooled, endogenous peroxidase activity was blocked 
with UltraVision Hydrogen Peroxide Block and non-specific bind was blocked using 
UltraVision Block reagent from UltraVision Quanto Detection System HRP DAB (Thermo 
Scientific/Lab Vision, Fremont, USA) for 10 minutes. The sections were then incubated in a 
humidified chamber with the following primary antibodies and accordingly with 
manufacturer’s specifications: mouse monoclonal antibody specific for DRP1 (1:100) ref. 
611112 from BD Biosciences and rabbit polyclonal antibody specific for UCP2 (1:200) ref. 
PA5-36383, from ThermoFisher Scientific. The slides were then washed and detected by 
using the UltraVision Quanto Detection System HRP DAB (Thermo Scientific/Lab Vision, 
Fremont, USA) accordingly with manufacturer’s specifications. All slides were 
counterstained with Mayer’s hematoxylin, dehydrated, and protected with a coverslip for 
microscopic examination.  
 Positive controls from previously tested kidney samples were used in every run. To 
assess specificity of the reaction, negative controls were included where tumor sections 
were not incubated with the primary antibody. 
 Table 2- Antibodies used and respective conditions used in the procedures of IHC. 
 
 
 
 
Primary 
antibody 
Antigen retrieval 
Antibody 
dilution 
Incubation 
time 
Incubation 
temperature 
DRP1 
1 mM EDTA pH 
9.00 solution 
1:100 Overnight 4ºC 
UCP2 
10 mM citrate buffer, 
pH 6.00 solution 
1:200 Overnight 4ºC 
 
 
 
29 
 
3.5. Evaluation of immunohistochemical staining  
 Immunostaining was blindly semi-quantitatively evaluated by three observers (ARL, 
VM and LS) without knowledge of any clinical information of the cases. The expression of 
DRP1 and UCP2 in tumor tissue was evaluated according to an immune reactive staining 
(IRS) score adapted from others (121-123). Immunohistochemical positivity was defined as 
cytoplasmic staining for UCP2 and DRP1, and immunostaining scores were based on the 
extension (E) of tumor cells immunostaining and immunostaining intensity (I). The extension 
of staining was scored as: 0, less than 10% of tumor cells stained; 1, 10%-25% of tumor 
cells stained; 2, 26%-50% of tumor cells stained; 3, 51%-75% tumor cells stained; and 4, 
more than 75% of tumor cells stained, and immunostaining intensity was evaluated 
according the following score scale: 0- absent, 1- weak, 2- moderate and 3- strong, as 
described in Table 3. A total score (IRS score) was then obtained by multiplying the 
extension and intensity score (IRS score=I x E), and ranged from 0 to 12 as shown in Table 
4. 
 For the analyses of DRP1 and UCP2 protein expression we considered three 
independent scores: IRS (indicating total level of proteins expression), Extension score, 
(indicating the percentage of tumor cells stained) and Intensity score (indicating the intensity 
of protein expression in tumor cells). Cases showing IRS score 4 or above, and/or intensity 
score 2 or above, and/or extension score 2 or above, were considered positive as described 
in Table 4. 
 
 
 
Table 3- Immunohistochemical classification for DRP1 and UCP2 
Intensity of staining (I) 
Absent 0 
Weak 1 
Moderate 2 
High 3 
Extent of stained tumor cells (E) 
<10% 0 
10 to 25% 1 
26 to 50% 2 
51 to 75% 3 
>75% 4 
 
 
 
 
30 
 
Table 4 - Immune reactive score for DRP1 and UCP2 
Immune reactive score 
(IRS)= E x I 
(Ranging from 0 to 12) 
Positive cases Negative cases 
IRS≥4 IRS<4 
I≥2 I<2 
E≥2 E<2 
 
 
3.6. Statistical analysis  
 The data collected in a database designed for this study was analyzed using the 
IBM SPSS 24.0 program. A descriptive analysis of the population was performed. Chi-
square test was used used to evaluate the statistical significance of the association of UCP2 
and DRP1 expression with the patients' clinical-pathological variables. The Pearson’s test 
was performed to evaluate correlation between UCP2 and DRP1 expression. 
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4. Results 
4.1. Patient characteristics and clinical-pathological parameters 
 The histopathological diagnosis of the thyroid tumors was the following: papillary 
thyroid cancer (PTC, n=153; 7 oncocytic and 146 non-oncocytic), follicular variant of 
papillary thyroid cancer (FVPTC, n=62; 9 oncocytic and 53 non-oncocytic), follicular thyroid 
cancer (FTC, n=23; 9 oncocytic and 14 non-oncocytic) and poorly differentiated thyroid 
cancer (PDTC, n=7; 1 oncocytic and 6 non-oncocytic) as described in Table 5 and illustrated 
in Figure 4. The demographic and clinical-pathological characteristics of the 245 patients 
and tumors are summarized in Table 6. The median follow-up time of 240 patients was 8.48 
(0.08-30.30) years. The study group was comprised of 48 (19.6%) males and 197 (80.4%) 
females, ranging in age from 11 to 83 years (mean ±SD age, 45.51 ±16.31 years). Distant 
metastases occurred in 33 (13.5%) patients. According to the 7th edition of AJCC 
classification, patient tumors were classified as stage I (115 cases, 46.9%), II (22 cases, 
9.0%), III (50 cases, 20.4%) and IV (58 cases, 23.7 %). Ninety (36.7%) of the carcinomas 
presented lymph node metastases, 80 (32.7%) had multifocality, 78 (31.8%) had vascular 
invasion, 104 (42.4%) had thyroid capsule invasion, and 80 (32.7%) had extrathyroidal 
extension.  
 
Table 5 - Histological diagnosis of the 245 thyroid tumors 
Histological diagnosis N of tumors (%) 
PTC 
Oncocytic 7 (4.6) 
Non-oncocytic 146 (95.4) 
FVPTC 
Oncocytic 9 (14.5) 
Non-oncocytic 53 (85.5) 
FTC 
Oncocytic 9 (39.1) 
Non-oncocytic 14 (60.9) 
PDTC 
Oncocytic 1 (14.3) 
Non-oncocytic  6 (85.7) 
 Total 245 
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Table 6 - Patient and tumor characteristics 
Clinicopathologic characteristics 
N of patients (%) 
n=245 (100%) 
Age 
<45 117 (47.8) 
≥45 128 (52.2) 
Mean age ± SD (range) 45.51 ±16.31 (9-83) 
Gender 
Female 197 (80.4) 
Male 48 (19.6) 
Histological diagnosis 
PTC 153 (62.4) 
FVPTC 62 (25.3) 
FTC 23 (9.4) 
PDTC 7 (2.9) 
Hürthle cell tumors 
Yes 26 (10.6) 
No 219 (89.4) 
Pathological stage at presentation 
I 115 (46.9) 
II 22 (9.0) 
III 50 (20.4) 
IV 58 (23.7) 
Tumor size 
≤4 cm 197 (80.4) 
>4 cm 48 (19.6) 
Figure 4 - Bar charts of the different histological diagnosis categorized by the presence 
or the absence of Hürthle cells. 
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Iodine treatment 
Yes 208 (84.9) 
No or unknown 37 (15.1) 
Number of iodine treatment 
=1 130 (53.1) 
≥2 77 (31.4) 
Unknown 38 (15.5) 
Mean iodine dosage ± SD(range) 183.50 ±233.03 (0-1350) 
Encapsulated tumors 
Yes 99 (40.4) 
No 85 (34.7) 
Unknown 61 (24.9) 
Vascular invasion 
Present 78 (31.8) 
Absent 120 (49.0) 
Unknown 47 (19.2) 
Multifocality 
Present 80 (32.7) 
Absent 137 (55.9) 
Unknown 28 (11.4) 
Thyroid capsule invasion 
Present 104 (42.4) 
Absent 108 (44.1) 
Unknown 33 (13.5) 
Extrathyroidal invasion 
Present 80 (32.7) 
Absent 136 (55.5) 
Unknown 29 (11.8) 
Lymph node metastases 
Present 90 (36.7) 
Absent 155 (63.3) 
Distant metastases 
Present 33 (13.5) 
Absent 210 (85.7) 
Unknown 2 (0.8) 
BRAFV600E mutation 
Wild 80 (32.7) 
Mutated 61 (24.9) 
Unknown 112 (45.7) 
End of follow-up disease status 
Yes 179 (73.1) 
No 53 (21.6) 
Unknown 13 (5.3) 
Mean time follow-up ± SD(range) (y) 8.48 ±6.09 (0.08-30.3) 
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4.2. Immunohistochemical expression of UCP2 and DRP1 
 Immunohistochemistry was performed to evaluate UCP2 and DRP1 expression in 
the thyroid carcinomas from our series, for which the extension and intensity of tumor cells 
stained is shown in Table 7. High and low expression of both DRP1 and UCP2 antibodies 
is illustrated in Figure 5.  
 Since the expression of UCP2 and DRP1 in normal adjacent thyroid tissue was 
usually weaker that in neoplastic tissue, with an IRS score of 3 or lower, we considered that 
positive expression or overexpression of UCP2 and DRP1 in thyroid carcinomas was 
defined by an IRS of 4 or higher. Using these criteria, positive and negative staining of 
UCP2 was observed in 177 (72.2%) and 68 (27.8%) of 245 cases, respectively, whereby 
DRP1 expression was classified as negative in 22 cases (9.0%) and positive in 223 cases 
(91.0%). Additionally, we classified UCP2 and DRP1 expression regarding the intensity and 
extension of tumor cells in all thyroid carcinomas as described in Table 7, and in Hürthle 
and non Hürthle cell tumors, separately, as described in Table 8 and 9, respectively. The 
distribution of UCP2 and DRP1 expression levels according the intensity and extension of 
the staining is described in Table 10. We verified that typically, DRP1 presented a higher 
IRS score than UCP2, when comparing the same individual cases as shown in Figure 6.  
 UCP2 expression was mainly cytoplasmic (Figure 7A), but UCP2 nuclear expression 
was also evidenced, yet not systematically evaluated (Figure 5). Scattered macrophages 
and muscular tissue were considered as internal positive controls for UCP2 whenever 
present (Figure 8B). A second internal and positive control for each tumor sample was the 
expression of UCP2 in normal adjacent tissue (Figure 8A). Although not significative 
(p=0.067), when we compared UCP2 expression among the different thyroid tumor 
histotypes, we verified that UCP2 expression was higher among PTC when compared to 
FTC and FVPTC combined, as demonstrated in Figure 9. 
 Regarding DRP1 expression, it was evident that the DRP1 antibody stained the 
cytoplasm, but not the nucleus (Figure. 7B and 10B). Like UCP2, scattered macrophages 
and normal adjacent thyroid tissue were considered as internal positive controls for DRP1. 
Comparing the DRP1 expression among the different thyroid tumor histotypes, we observed 
that DRP1 expression was significantly higher in PTC when compared to FTC and FVPTC 
combined, when assessed by intensity score (p=0.024) as shown in Figure 9. 
 Figure 9 represents the comparison of the expression of the two mitochondrial 
proteins with the same IRS score=9 in the same PTC case and Figure 10 illustrates invasion 
of adipose tissue in tumors with higher expression of UCP2 and DRP1. 
 
 
 
37 
 
 
 
 
Table 7 - UCP2 and DRP1 expression scores according intensity, extension and IRS score 
in all 245 cases from our series, including Hürthle cell tumors and non-Hürthle cell tumors 
 
N=245 
Intensity Score, N of 
tumors (%) 
Extension Score, N of 
tumors (%) 
IRS score, N of 
tumors (%) 
Negative Positive Negative Positive Negative Positive 
UCP2 121 (49.4) 124 (50.6) 26 (10.6) 219 (89.4) 68 (27.8) 177 (72.2) 
DRP1 48 (19.6) 197 (80.4) 9 (3.7) 236 (96.3) 22 (9.0) 223 (91.0) 
Figure 5- Representative immunohistochemical staining of thyroid specimens from our 
series, illustrating high and low expression of DRP1 and UCP2 antibodies, and nuclear 
expression of UCP2 antibody, present in some of the tumors. All pictures were taken with 
20x 
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Table 8 - UCP2 and DRP1 expression scores according intensity, extension and final score 
in non-Hürthle cell tumors 
 
 
Table 9 - UCP2 and DRP1 expression scores according intensity, extension and final score 
in Hürthle cell tumors 
 
 
Table 10 - Distribution of UCP2 and DRP1 expression levels according the intensity and 
extension 
 
N=219 
Intensity Score, N of 
tumors (%) 
Extension Score, N of 
tumors (%) 
IRS score, N of 
tumors (%) 
Negative Positive Negative Positive Negative Positive 
UCP2 114 (52.1) 105 (47.9) 26 (11.9) 193 (88.1) 67 (30.6) 152 (69.4) 
DRP1 42 (19.2) 177 (80.8) 9 (4.1) 210 (95.9) 22 (10.0) 197 (90.0) 
N=26 
 
Intensity Score, N of 
tumors (%) 
Extension Score, N of 
tumors (%) 
IRS score, N of 
tumors (%) 
Negative Positive Negative Positive Negative Positive 
UCP2 7 (26.9) 19 (73.1) 0 (00.0) 26 (100.0) 1 (3.8) 25 (96.2) 
DRP1 6 (23.1) 20 (76.9) 0 (00.0) 26 (100.0) 0 (00.0) 26 (100.0) 
N=245 
Intensity, N of tumors (%) 
0 
(No staining) 
1 
(weak) 
2 
(moderate) 
3 
(strong) 
 
UCP2 18 (7.3) 105 (42.7) 83 (33.7) 40 (16.3) 
DRP1 4 (1.6) 44 (17.9) 121 (49.2) 77 (31.3) 
N=245 
Extension, N of tumors (%) 
0 
(<10%) 
1 
(10-25%) 
2 
(26-50%) 
3 
(51-75%) 
4 
(>75%) 
UCP2 18 (7.3) 8 (3.3) 64 (26.0) 64 (26.0) 92 (37.4) 
DRP1 4 (1.6) 5 (2.0) 48 (19.5) 92 (37.4) 97 (39.4) 
 
 
 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 - Tumor cells showing high expression of UCP2 (A; IRS score= 6) 
and DRP1 (B; IRS score=9) expression scores in the same PTC case. All 
pictures were taken with 2.5x magnification. 
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Figure 7- Tumor cells showing strong cytoplasmic expression for UCP2 (A) and DRP1 
(B) with an IRS score= 12.  All pictures were taken with 10x magnification. 
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Figure 8 - Internal positive controls for UCP2. A – Normal adjacent 
thyroid tissue expressed low levels of UCP2 and functioned as an 
internal positive control; B – UCP2 is strongly expressed in muscular 
tissue, acting as an internal positive control. All pictures were taken 
with 20x magnification. 
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Figure 9 -  Although not statistically significant for UCP2 (p=0.067), the expression of both 
DRP1 and UCP2 proteins is higher among PTC when compared to FVPTC and FTC 
combined, regarding the intensity score (p=0.024). PDTC and poor prognosis variant of 
PTC (solid, diffuse, diffuse sclerosing, tall cell, columnar cell, cribriform-cell) were excluded 
from this analysis (Statistically significant difference: * - p< 0.05: qui-square test). 
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Figure 10 - Comparison of the expression of the two mitochondrial proteins with the 
same IRS score=9 in the same PTC. A – Expression of UCP2 is mainly cytoplasmic with 
some nucleus stained (20x); B – DRP1 expression is cytoplasmic without nuclear 
expression. All pictures were taken with 20x magnification. 
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Figure 11- High expression of DRP1 (A) and UCP2 (B) in thyroid tumor cells showing 
invasion of adipose tissue. All pictures were taken with 20x magnification. 
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4.3. UCP2 is highly expressed in Hürthle cell tumors 
 Each different thyroid histotype can present oncocytic and non-oncocytic features. 
The cells of oncocytic tumors show distinctive granular, voluminous and eosinophilic 
cytoplasm. The Hürthle (or oncocytic) cell tumors present the granular and large cytoplasm 
due to the high number of mitochondria present in cells. 
 Among the 26 Hürthle cell tumors, we observed that UCP2 was highly expressed 
(positive) in 25 cases and negative in 1 case (with an IRS score= 3), and DRP1 was highly 
expressed in all 26 cases (Figure 12). When we compared the expression of both 
mitochondrial proteins between Hürthle and non-Hürthle cell carcinomas, we verified that 
the expression of UCP2 was significantly higher in Hürthle cell tumors regarding the IRS 
score (p=0.009) and intensity score (p=0.004) as shown in Figure 13A and, although not 
statistically significative, the expression of DRP1 was as well higher in Hürthle cell tumors 
when compared to non-Hürthle cell tumors as illustrated in Figure 13B.  
 Since both mitochondrial proteins are highly expressed in Hürthle cell tumors, we 
further investigate the relationship between UCP2 and DRP1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12 - Hürthle cells with high expression of UCP2 (A) and DRP1 (B) as 
assessed by an IRS score≥ 4. All pictures were taken with 20x magnification. 
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Figure 13 - A - Expression of UCP2 is significantly higher in Hürthle cell tumors (oncocytic) 
when compared to non-Hürthle cell tumors (non-oncocytic) according to the IRS score (p-
value=0.002); B -Although not significantly, the expression of DRP1 is higher in Hürthle cell 
tumors when compared to non-Hürthle cell tumors (IRS score, p-value= 0.091). (Statistically 
significant difference: * - p< 0.05: qui-square test). 
 
4.4. Correlation between UCP2 and DRP1 expression 
 Recently, it has been reported that UCP2 may regulate DRP1 expression (68). To 
assess whether there is a correlation between the expression of UCP2 and DRP1, we 
further evaluated the interaction of both mitochondrial proteins in Hürthle and non-Hürthle 
tumor tissue. A statistical analysis was performed by correlation analysis to determine if 
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there was any relation between UCP2 and DRP1 expression. A statistically significant 
positive correlation was obtained between UCP2 and DRP1 expression for Hürthle cell 
tumors (intensity score, p=0.044) and for non-Hürthle cell tumors (IRS score, p=0.002; 
intensity score, p=0.037), as described in Table 11 and 12, respectively. Accordingly, the 
relation between UCP2 and DRP1 appears to be not restricted to Hürthle cells tumors. 
 
Table 11 - Pearson correlation between UCP2 and DRP1 expression in Hürthle cell tumors. 
Statistically significant difference: * - p< 0.05: Pearson test) 
 N 
Pearson 
correlation 
p-value 
UCP2 vs. DRP1 IRS score 26 0.257 p=0.205 
UCP2 vs DRP1 Intensity score 26 0.397 p=0.044* 
UCP2 vs. DRP1 Extension score 26 0.120 p=0.561 
 
 
Table 12 - Pearson correlation between UCP2 and DRP1 expression in non-Hürthle cell 
tumors. Statistically significant difference: * - p< 0.05: Pearson test) 
 N 
Pearson 
correlation 
p-value 
UCP2 vs. DRP1 IRS score 219 0.212 p=0.002* 
UCP2 vs DRP1 Intensity score 219 0.141 p=0.037* 
UCP2 vs. DRP1 Extension score 219 0.062 p=0.361 
 
 
4.5. Association of UCP2 expression with clinical-pathological features 
 
 The association of UCP2 expression with the clinical-pathological characteristics of 
the patient series was further evaluated, and is summarized in Table 13, 14 and 15, 
according to the IRS, intensity and extension scores, respectively. Expression of UCP2 was 
not associated with patients’ age (<45 years old versus ≥45 years old), patients’ gender, 
pathological stage of tumor, iodine treatment (1 versus ≥2), vascular invasion, multifocality, 
thyroid capsule invasion extrathyroidal invasion, lymph node metastases, and BRAFV600E 
mutation.  Interestingly, a higher expression of UCP2 was significantly associated with non-
encapsulated tumors when assessed by IRS score (p=0.022) as shown in Figure 14. 
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 Additionally, we did find a significant association between tumors without distant 
metastases and higher UCP2 expression as assessed by the IRS score (p=0.005) and 
intensity score (p=0.001) as shown in Figure 15. These results were independent from the 
histotype, with a statiscally significant association for PTC, and the same trend also 
observed for FTC, although not statiscally significant, as presented in Table 13. Likewise, 
we verified the same association for DRP1 expression according to the IRS score (p=0.048) 
as shown in Figure 16. Furthermore, we verified that high levels of DRP1 were associated 
to thyroid capsule invasion regarding the intensity score (p=0.011) as demonstrated in 
Figure 17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14 - UCP2 expression is significantly higher in non-encapsulated 
tumors according the to IRS score (p=0.022). (Statistically significant 
difference: * - p< 0.05: qui-square test). 
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Figure 15 - UCP2 expression is significantly higher in tumors without distant 
metastases according to the IRS score (p=0.005). (Statistically significant 
difference: * - p< 0.05: qui-square test). 
Figure 16 - DRP1 expression is significantly higher in tumors with distant 
metastases according to IRS score (p=0.048). (Statistically significant 
difference: * - p< 0.05: qui-square test) 
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Table 13 Association between UCP2 expression in PTC and FTC, separately. (Statistically 
significant difference: * - p< 0.05: qui-square test) 
 
 
 
PTC 
N=152 
 IRS score p-value 
  Negative Positive 
0.026* 
Distant metastasis 
Absent 30 (22.2) 105 (77.8) 
Present 8 (47.1) 9 (52.9)  
FTC 
N=23 
    
Distant metastasis 
Absent 3 (21.4) 11 (78.6) 
0.416 
Present 3 (37.5) 5 (62.5) 
Figure 17 -  DRP1 expression is significantly higher in tumors with thyroid 
capsule invasion according to the intensity score (p=0.011). (Statistically 
significant difference: * - p< 0.05: qui-square test). 
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Table 14 - Association between clinical-pathological characteristics and UCP2 expression 
regarding IRS score. (Statistically significant difference: * - p< 0.05: qui-square test) 
n=245 (100%) 
 
Variables 
 
IRS score 
Negative Positive p-value 
Age 
<45 years-old 32 (27.4) 85 (72.6) 
1,000 
≥45 years-old 36 (28.1) 92 (71.9) 
Gender 
Female 53 (26.9) 144 (73.1) 
0,546 
Male 15 (31.3) 33 (68.8) 
Histological diagnosis 
PTC+FVPTC vs. 
 
FTC 
50 (25.4) 147 (74.6) 
0.601 
7 (30.4) 16 (69.6) 
PTC vs. 
 
FTC+FVPTC 
30 (22.2) 105 (77.8) 
0.116 
27 (31.8) 58 (68.2) 
Oncocytic tumors 
Yes 1 (3.8) 25 (96.2) 
0.002* 
No 67 (30.6) 152 (69.4) 
Pathological stage at 
presentation 
I+II 37 (26.8) 101 (73.2) 
0.708 
III+IV 31 (29.0) 76 (71.0) 
Tumor size 
≤4 cm 55 (27.9) 142 (72.1) 
1.000 
>4 cm 13 (27.1) 35 (72.9) 
Iodine treatment 
Yes 59 (28.4) 149 (71.6) 
0.694 
No or unknown 9 (24.3) 28 (75.7) 
Number of iodine 
treatment 
=1 37 (28.5) 93 (71.5) 
0.986 
≥2 22 (28.6) 55 (71.4) 
Unknown 38 (15.5)   
Encapsulated tumors 
Yes 36 (36.4) 63 (63.6) 
0.022* 
No 17 (20.0) 68 (80.0) 
Unknown 61 (24.9) 
Vascular invasion 
Present 19 (24.4) 59 (75.6) 
0.264 
Absent 39 (32.5) 81 (67.5) 
Unknown 47 (19.2) 
Multifocality 
Present 24 (30.0) 56 (70.0) 
0.477 
Absent 35 (25.5) 102 (74.5) 
Unknown 28 (11.4) 
Thyroid capsule invasion 
Present 29 (27.9) 75 (72.1) 
0.986 
Absent 30 (27.8) 78 (72.2) 
Unknown 33 (13.5)  
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Extrathyroid invasion 
Present 20 (25.0) 60 (75.0) 
0.636 
Absent 39 (28.7) 97 (71.3) 
Unknown 29 (11.8)  
Lymph node metastases 
Present 31 (34.4) 59 (65.6) 
0.075 
Absent 37 (23.9) 118 (76.1) 
Distant metastases 
Present 16 (48.5) 17 (51.5) 
0.004* 
Absent 51 (24.3) 159 (75.7) 
Unknown 2 (0.8) 
BRAFV600E mutation 
Wild 33 (41.3) 47 (58.8) 
1.000 
Mutated 21 (39.6) 32 (60.4) 
Unknown 112 (45.7) 
End of follow-up disease 
status 
Yes 47 (26.3) 132 (73.7) 
0.405 
No 17 (32.1) 36 (67.9) 
Unknown 13 (5.3) 
 
 
Table 15 - Association between clinical-pathological characteristics and UCP2 expression 
regarding intensity score. (Statistically significant difference: * - p< 0.05; ** - p< 0.001: qui-
square test) 
N=245 (100%) 
 
Variables 
Intensity score 
Negative Positive p-value 
Age 
<45 years-old 52 (44.4) 65 (55.6) 
0.160 
≥45 years-old 69 (53.9) 59 (46.1) 
Gender 
Female 93 (47.2) 104 (52.8) 
0.198 
Male 28 (58.3) 20 (41.7) 
Histological diagnosis 
PTC+FVPTC vs. 
 
FTC 
93 (47.2) 104 (52.8) 
0.509 
13 (56.5) 10 (43.5) 
PTC vs. 
 
FTC+FVPTC 
60 (44.4) 75 (55.6) 
0.169 
46 (54.1) 39 (45.9) 
Oncocytic tumors 
Yes 7 (26.9) 19 (73.1) 
0.021* 
No 114 (52.1) 105 (47.9) 
Pathological stage at 
presentation 
I+II 61 (44.2) 77 (55.8) 
0.072 
III+IV 60 (56.1) 47 (43.9) 
Tumor size 
≤4 cm 100 (50.8) 97 (49.2) 
0.423 
>4 cm 21 (43.8) 27 (56.3) 
Iodine treatment 
Yes 104 (50.0) 104 (50.0) 
0.722 
No or unknown 17 (45.9) 20 (54.1) 
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Number of iodine 
treatment 
=1 62 (47.7) 68 (52.3) 
0.389 
≥2 42 (54.5) 35 (45.5) 
Unknown 38 (15.5)   
Encapsulated tumors 
Yes 59 (59.6) 40 (40.4) 
0.012* 
No 34 (40.0) 51 (60.0) 
Unknown 61 (24.9) 
Vascular invasion 
Present 38 (48.7) 40 (51.3) 
0.771 
Absent 62 (51.7) 58 (48.3) 
Unknown 47 (19.2) 
Multifocality 
Present 39 (48.8) 41 (51.3) 
0.888 
Absent 69 (50.4) 68 (49.6) 
Unknown 28 (11.4) 
Thyroid capsule invasion 
Present 54 (51.9) 50 (48.1) 
0.410 
Absent 49 (45.4) 59 (54.6) 
Unknown 33 (13.5)  
Extrathyroid invasion 
Present 41 (51.3) 39 (48.8) 
0.552 
Absent 64 (47.1) 72 (52.9) 
Unknown 29 (11.8)  
Lymph node metastases 
Present 52 (57.8) 38 (42.2) 
0.064 
Absent 69 (44.5) 86 (55.5) 
Distant metastases 
Present 25 (75.8) 8 (24.2) 
0.001** 
Absent 95 (45.2) 115 (54.8) 
Unknown 2 (0.8) 
BRAFV600E mutation 
Wild 51 (63.8) 29 (36.3) 
0.298 
Mutated 29 (54.7) 24 (45.3) 
Unknown 112 (45.7) 
End of follow-up disease 
status 
Yes 85 (47.5) 94 (52.5) 
0.211 
No 31 (58.5) 22 (41.5) 
Unknown 13 (5.3) 
 
Table 16 - Association between clinical-pathological characteristics and UCP2 expression 
regarding extension score. (Statistically significant difference: * - p< 0.05: qui-square test) 
N=245 (100%) 
 
Variables 
 
Extension score 
Negative Positive p-value 
Age 
<45 years-old 12 (10.3) 105 (89.7) 
1.000 
≥45 years-old 14 (10.9) 114 (89.1) 
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Gender 
Female 22 (11.2) 175 (88.8) 
0.794 
Male 4 (8.3) 44 (91.7) 
Histological diagnosis 
PTC+FVPTC vs. 
 
FTC 
17 (8.6) 180 (91.4) 
0.248 
4 (17.4) 19 (82.6) 
PTC vs. 
 
FTC+FVPTC 
9 (6.7) 126 (93.3) 
0.067 
12 (14.1) 73 (85.9) 
Oncocytic tumors 
Yes 0 (0.00) 26 (100.0) 
0.087 
No 26 (11.9) 193 (88.1) 
Pathological stage at 
presentation 
I+II 14 (10.1) 124 (89.9) 
0.787 
III+IV 12 (11.2) 95 (88.8) 
Tumor size 
≤4 cm 18 (9.1) 179 (90.9) 
0.129 
>4 cm 8 (16.7) 40 (83.3) 
Iodine treatment 
Yes 24 (11.5) 184 (88.5) 0.388 
 No or unknown 2 (5.4) 35 (94.6) 
Number of iodine 
treatment 
=1 17 (13.1) 113 (86.9) 
0.502 
≥2 7 (9.1) 70 (90.9) 
Unknown 38 (15.5)   
Encapsulated tumors 
Yes 14 (14.1) 85 (85.9) 
0.250 
No 7 (8.2) 78 (91.8) 
Unknown 61 (24.9) 
Vascular invasion 
Present 7 (9.0) 71 (91.0) 
0.641 
Absent 14 (11.7) 106 (88.3) 
Unknown 47 (19.2) 
Multifocality 
Present 6 (7.5) 74 (92.5) 
0.629 
Absent 14 (10.2) 123 (89.8) 
Unknown 28 (11.4) 
Thyroid capsule invasion 
Present 8 (7.7) 96 (92.3) 
0.360 
Absent 13 (12.0) 95 (88.0) 
Unknown 33 (13.5)  
Extrathyroid invasion 
Present 5 (6.3) 75 (93.8) 
0.238 
Absent 16 (11.8) 120 (88.2) 
Unknown 29 (11.8)  
Lymph node metastases 
Present 10 (11.1) 80 (88.9) 
0.833 
Absent 16 (10.3) 139 (89.7) 
Distant metastases 
Present 7 (21.2) 26 (78.8) 
0.026* 
Absent 18 (8.6) 192 (91.4) 
Unknown 2 (0.8)  
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BRAFV600E mutation 
Wild 16 (20.0) 64 (80.0) 
0.081 
Mutated 4 (7.5) 49 (92.5) 
Unknown 112 (45.7) 
End of follow-up disease 
status 
Yes 15 (8.4) 165 (91.6) 
0.062 
No 10 (18.9) 43 (81.1) 
Unknown 13 (5.3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
  
 
 
 
57 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
  
 
 
 
59 
 
5. Discussion  
 The acquisition of the oncocytic phenotype in tissues remains poorly understood. 
The accumulation of dysfunctional mitochondria specifically in Hürthle cell tumors indicate 
that the unbalance between mitochondrial fusion and fission might trigger Hürthle cell 
transformation (30). Indeed, the control of the mitochondrial mass is achieved by the 
equilibrium between mitochondrial biogenesis and degradation (124), and fusion and fission 
are key processes for this balance to occur. However, the exact mechanism responsible for 
this abnormal mitochondrial accumulation remains unclear. DRP1 is the main mediator of 
mitochondrial fission, certifying equal division of mitochondria to the daughter cells and 
regulating the selective removal of damaged mitochondria by the process of mitophagy, 
thereby preserving a healthy mitochondrial network (44). Furthermore, mitophagy is a 
phenomenon that serves as a turnover mechanism that maintains cellular homeostasis and 
prevents cell death (45). It has been demonstrated that DRP1 inhibition leads to mitophagy 
suppression, and therefore DRP1 may control the level of mitochondrial hyperplasia. Thus, 
mitophagy mediated by DRP1 might be a determinant process in oncocytic phenotype, 
allowing mitochondrial accumulation (125). Indeed, our group have recently verified that 
DRP1 is overexpressed in Hürthle cell tumors, suggesting that mitochondrial dynamics are 
dysregulated in Hürthle cells (34). Accordingly, in the present study we also confirmed that 
DRP1 expression was significantly higher in Hürthle cell tumors when compared to non-
Hürthle cell tumors, further strengthening the hypothesis that upregulation of mitochondrial 
fission is associated to the oncocytic phenotype. In contrast with non-Hürthle cell tumors, 
Hürthle cell tumors are marked by the high prevalence of alterations in mtDNA and nuclear 
DNA (126).  Most of genetic alterations include large deletions of mtDNA, mutations in 
mtDNA genes and mutations in nuclear genes coding for mitochondrial proteins (30). Genes 
encoding complex I subunits in the mtDNA are the most susceptible to mutation (124). 
GRIM-19 mutations are the only nuclear gene mutations specific of Hürthle cell tumors 
reported to date. Downregulation of GRIM-19 confers growth advantage apparently via 
reduced apoptosis (127). The large mtDNA deletion, usually mentioned as the “common 
deletion” is a predominant alteration observed in Hürthle cells. This deletion eliminates 
about one-third of total mtDNA, which result in severe impairment of OXPHOS (124). 
Additionally, mutations in complex I genes, as well as mutations in other genes of the 
mitochondrial respiratory chain complexes, may also result in OXPHOS system impairment 
(30, 124, 126). It is believed that initial mtDNA mutations may contribute to increase ROS 
levels, further triggering the occurrence of additional mutations in a feed-forward loop (125) 
It has been suggested that alterations in mtDNA genes affecting complex I are linked to 
 
 
 
60 
 
predisposition to thyroid tumorigenesis (30). Indeed, there is strong evidence that Hürthle 
cell phenotype is associated with mtDNA mutations, namely in complex I genes (126, 128), 
supporting that mtDNA mutations in complex I subunits may be the main cause of 
mitochondrial hyperplasia, ensuring characteristic Hürthle cell phenotype (125, 126). The 
most well-established hypothesis to clarify how mtDNA mutations lead to mitochondrial 
hyperplasia in Hürthle cells is the compensatory effect theory, according to which defective 
mitochondria try to resist the OXPHOS impairment by promoting mitochondrial biogenesis. 
Interestingly, it has been demonstrated that Hürthle cell tumors exhibit a remarkable 
upregulation of mtDNA genes implicated in protein metabolism, which leads to 
mitochondrial proliferation (129). Indeed, it was recently reported that proteins involved in 
mitochondrial fission (DRP1), mitophagy, proteolysis and antioxidant response were 
significantly increased in type I endometrial cancer as an adaptive response to respiratory 
complex I deficiency, suggesting that these processes are activated as a mitochondrial 
adaptation to mitochondrial dysfunction (130). In particular, the authors demonstrated a 
significant increase of DRP1 protein levels (130). Moreover, it has been reported that 
mitochondrial fission and biogenesis contribute in cellular adaptation to respiratory chain 
dysfunction in skin fibroblasts (131).   
 Normal iodine and thyroid hormone metabolism generates oxidative stress through 
elevated levels of mitochondrial ROS which may explain the high prevalence of oncocytic 
phenotype in thyroid cells (121). The excessive amount of ROS can result in mutagenic 
genetic events, namely in mtDNA, leading to mitochondrial dysfunction. On the other hand, 
increased ROS production by the impaired OXPHOS capacity of the increased number of 
mitochondria in Hürthle cells may stimulate an increase of UCP2 levels. The impairment of 
mitochondrial OXPHOS may also be involved in mitochondrial accumulation, leading to 
mitochondrial overproduction to offset energy deficits (71). Due to OXPHOS impairment, 
Hürthle cells are forced to shift their metabolism to glycolysis as an alternative metabolic 
pathway for energy production and compensating for OXPHOS dysfunction, a commonly 
observed characteristic of cancer cells that is usually known as the “Warburg effect” (100, 
124).  Interestingly, it has been suggested that the Warburg effect is mediated by UCP2 
(99). In fact, in addition to reducing mitochondrial ATP production through uncoupling, 
UCP2 may also reduce OXPHOS by promoting pyruvate efflux from the mitochondria, 
thereby restricting glucose availability for respiration (76). This may increase the high rate 
of glycolysis in cancer cells. Thus, these findings may suggest that higher expression of 
UCP2 can directly contribute to maintaining the Warburg phenotype induced by mtDNA in 
Hürthle cells.  
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 Previous research by Savagner et al. demonstrated that UCP2 was highly 
expressed in all 22 Hürthle cell tumors (100%) when compared with their controls (71). 
Accordingly, we also demonstrated higher UCP2 expression in Hürthle cell tumors when 
compared to non-Hürthle cell tumors, indicating that levels of UCP2 are predominantly 
higher in Hürthle cell tumors. Therefore, highly UCP2 expression observed in Hürthle cells 
seem to control the excessive amounts of ROS caused by the impaired OXPHOS capacity. 
Moreover, several studies in non-oncocytic tumors have proposed that mitochondrial 
uncoupling is implicated in the regulation of oxidative stress, suggesting that UCP2 acts as 
part of the antioxidant systems in the cell  (73, 75, 132). Collins et al. observed that UCP2 
overexpression in HepG2 human hepatoblastoma cells lowers intracellular ROS levels and 
attenuates apoptosis (133). Likewise, in human colon tumor tissues, UCP2 acts as an 
adaptive mechanism to reduce oxidative stress (103). In Horimoto’s colon cancer study 
(103), UCP2 overexpression was suggested to protect a variety of cell types from apoptosis, 
and it was postulated that the cytoprotective effect of UCP2 is likely based on a reduction 
in mitochondrial ROS generation. Consistent with these findings, UCP2 is known to be a 
negative regulator of ROS and a sensor of oxidative stress (92). Thus, absence of UCP2 is 
associated with increased ROS production, while enhanced UCP2 expression protect cells 
from injury and death related to oxidative stress (78, 91). In this regard, similarly to the 
Hürthle cell tumors, UCP2 expression in non-Hürthle cell tumors is enhanced to attenuate 
the level of ROS to prevent oxidative injury.   
 The purpose of this study was to demonstrate that UCP2 plays a key role in the 
regulation of DRP1 expression in DTC, and that this regulation may even be more 
expressive in Hürthle cells tumours, highlighting its putative role in the oncocytic phenotype. 
This hypothesis was founded in a recent study that, based on complementary genetic 
manipulations of UCP2 through either whole-body knockout of UCP2 or SF1-neuron-
restricted re-expression of UCP2, verified that DRP1-mediated mitochondrial fission 
activation depends on UCP2 (68). Accordingly, we observed a statistically significant 
positive correlation between UCP2 and DRP1 expression for Hürthle and non-Hürthle cell 
tumors supporting the hypothesis that DRP1 is mediated by UCP2. Therefore, the 
relationship between UCP2 and DRP1 appears to be not restricted to Hürthle cells tumors, 
as we expected, suggesting that this relation may be extended to other cancer cell 
phenotypes. Indeed, despite the higher expression of UCP2 and DRP1 in Hürthle cell 
tumors when compared to non-Hürthle cell tumors, DRP1 and UCP2 were highly expressed 
in 90% (197/219) and 69.4% (152/219) of the non-Hürthle cell tumors, respectively. In 
addition, UCP2 and DRP1 expression was found to be highly expressed in several other 
cancers. Significant upregulation of UCP2 was observed in colon cancer (101), head, neck, 
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skin, pancreas and prostate cancers (102), breast cancer and most other tumors (99). 
Likewise, DRP1 expression was found to be increased in several cancers such lung cancer 
(58), melanoma (63), breast cancer (59). Interestingly, Cormio et al. demonstrated that the 
several proteins’ expression levels , including DRP1, are independent of mtDNA mutations, 
characteristic of oncocytic tumors, further suggesting that the increase of such proteins may 
not be restricted to oncocytic tumors (130). Additionally, Brandi et al. also detected that 
UCP2 decreases the consumption of oxygen, without changing the total amount of 
mitochondrial DNA, suggesting that inhibition of oxidative phosphorylation by UCP2 is 
independent of mitochondria amount alteration (82).These findings may help explain the 
elevated levels of UCP2 and DRP1 we found in both oncocytic and non-oncocytic tumors, 
regardless of the putative presence of mitochondrial DNA alterations. Overall, our results 
support the hypothesis that the high expression of DRP1 in Hürthle and non-Hürthle cell 
tumors is regulated by UCP2. Since UCP2 is able to control mitochondrial oxidative stress 
(76), we hypothesize that UCP2 may be triggered as a protective response to the ROS 
increase and consequently stimulate DRP1 activation as an adaptive mechanism. 
 Beyond the correlation we have found between DRP1 and UCP2 expression, we 
verified that DRP1 is highly expressed in 91% of cases, while UCP2 was highly expressed 
in only 72.2% of the cases, indicating that DRP1 may be regulated through other 
mechanisms. Indeed, it has been demonstrated that hypoxia is able to upregulate DRP1 in 
gliobastoma U251 cell line (134). Additionally, DRP1 is regulated by several post-
translational modifications that may help to explain the higher expression of this protein 
(57). Finally, the differences we found in positivity rates between UCP2 and DRP1 may also 
be explained by the intrinsic low levels of UCP2 protein as noticed before. 
 One remarkeble feature of increased UCP2 levels in cancer is the UCP2-induced 
chemo-resistance. Indeed, knockdown or inhibition of UCP2 triggers apoptosis and 
increases chemotherapeutic sensitivity in many cancer cells (96, 105, 106). Several studies 
have demonstrated that UCP2 is involved not only in cancer cell transformation but also in 
chemoresistance (135-137). In 2008, Z. Derdak et al. demonstrated that overexpression of 
UCP2 inhibit ROS accumulation and apoptosis, leading to chemoresistance in colon cancer 
cells (90). A more recent study verified that breast cancer cells are more sensitive to 
cytotoxic treatments in combination with UCP2 silencing due to an increase in ROS 
production, thus suggesting an inter-talk between UCP2 expression levels and oxidative 
stress (96). In fact, elevated levels of UCP2 mRNA in cell lines derived from pancreatic 
adenocarcinoma, non-small-cell lung cancer, and bladder carcinoma facilitates resistance 
to the chemotherapeutic drug gemcitabine, while downregulation of UCP2 results in signifi-
cantly increased cell death following chemotherapy (135). Moreover, UCP2 inhibition 
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sensitized multidrug-resistant acute promyelocytic leukemia cell lines to cytotoxic agents 
(137). These studies suggest that inhibition of UCP2 is able to improve the efficacy of 
chemotherapeutics drugs and expose cancer cells to oxidative stress and consequently kill 
them. In this regard, UCP2 may be a molecular target of great usefulness in novel treatment 
strategies. Moreover, a recent study demonstrated that UCP2 expression levels in 58 
patients with locally advanced uterine cervical cancer are associated with the likely 
effectiveness of neoadjuvant chemotherapy. Patients were divided in two groups according 
the UCP2 expression and the authors verified that the low expression group was more 
sensitive to neoadjuvant chemotherapy than the high expression group. Additionally, they 
verified that the inhibition of UCP2 by genipin enhances the sensitivity of cervical cancer 
cells to cisplatin (138). Therefore, UCP2 may represent a potential predictive marker of 
chemoresistance. 
 Because TC prognosis depends from the interplay between clinical and biological 
factors, we further evaluated the association between these characteristics with UCP2 
expression. We verified that the expression of UCP2 was not associated with patients’ age 
(<45 years old versus ≥45 years old), patients’ gender, pathological stage of tumor, iodine 
treatment, vascular invasion, multifocality, thyroid capsule invasion, extrathyroidal invasion, 
lymph node metastases, and BRAFV600E mutation. Interestingly, higher expression of UCP2 
was significantly associated with non-encapsulated tumors, which can be explained by the 
higher prevalence of UCP2 expression in PTC, known to be non-capsulated tumors in a 
majority of cases. Contrary to our initial expectations, we did find an apparently 
counterintuitive significant association between tumors without distant metastases and high 
UCP2 expression. In fact, other studies demonstrated that increased UCP2 expression is 
associated with the degree of neoplastic change in human colon cancer cells (103), and a 
similar association of UCP2 levels with clinical stages of colon cancer was also described 
(101). Likewise, Won et al. demonstrated that UCP2 overexpression was significantly 
correlated with higher histological grade in invasive ductal breast carcinoma (139). 
Additionally, in breast cancer patients, UCP2 expression correlates with poor prognosis 
(96). Accordingly, overexpression of UCP2 in breast cancer cells increased their 
tumorigenic phenotype, both in vitro and in vivo in a mouse xenograft model (99). However, 
the role of UCP2 as a tumor-promoting carrier has also been questioned by several other 
studies, where overexpression of UCP2 was reported to repress malignant properties of 
human cancer lines in vitro when injected in nude mice (140). This is in accordance with the 
association we found between elevated UCP2 expression and tumors without distant 
metastases, suggesting that UCP2 may play a role in the early local tumor niche adaptation 
and survival of tumor cells, playing a role in the invasive traits of tumors, but may not play 
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a role in the migration of tumor cells to different organs. Indeed, to our knowledge, the 
association between UCP2 expression and distant metastases has never been described 
before in literature. Furthermore, UCP2 is very unsTable, with a half-life close to 30 minutes 
(141, 142), compared to 30 hours for its homologue UCP1, suggesting that UCP2 is able to 
regulate rapid biologic responses, and may be not the ideal candidate to regulate the long-
term process that represents distant mestastization in DTC, especially if we think that most 
of the patients that do evolve to present distant metastases have gone through a series of 
therapeutic interventions, mainly based on iodine treatment and TSH suppression, which 
might contribute to the adaptive mechanisms of tumor cells in the primary tumor which 
eventually, select for a sub-clone of cells that can go through the process of detachment, 
extravasion, migration, intravasion and ultimately homing and survival in the metastatic 
niche. Additionally, these capacities may go beyond the continuous adaptation of the tumor 
cell metabolism to a stressing environment, and may also depend from other mechanisms, 
including molecular ones. Indeed, TERT promoter mutations have recently been described 
and associated with distant metastases and poor survival in papillary and follicular 
carcinomas (13).  
 Curiously, we verified that elevated levels of DRP1 expression is also associated 
with tumors without distant metastases, supporting the idea that DRP1 is regulated by 
UCP2. This association is contradictory to what has been documented in to other studies in 
different tumor models. Indeed, using a non-metastatic breast cancer cell line MCF7 and 
two metastatic cell lines, MDA-MB-231 and MDA-MB-436, Zhao et al. (59) have showed an 
increased expression of DRP1 of 2 to 2.5-fold in the metastatic cell lines as compared to 
the non-metastatic, which was accompanied by a 50% reduction in the expression of Mfn1. 
Likewise, Han et al. (134) described a similar pattern of DRP1 expression in metastatic 
breast cancer cell lines, under hypoxic conditions. However, the significant association we 
found between higher DRP1 expression and thyroid capsule invasion may suggest that 
DRP1 may be more relevant in tumor progression and local invasion mechanisms, as 
compared to promoting distant metastization, at least in humans. Indeed, it has been 
suggested that upregulation of DRP1 can be an early event in invasive breast cancer 
development (59), as it was in other tumor models as melanoma (64) in the very specific 
context of BRAFV600E mutations. The fact that we did not see any association between BRAF 
mutations and UCP2 and DRP1 expression is not totally unexpected, as conflicting data 
supporting its role prognosis marker, including its association with distant metastases, have 
been published. Why the correlation between both UCP2 and DRP1 and distant metastases 
follows into opposite directions needs further exploitation and explanation. It is however 
important to highlight that, as previously mentioned, normal iodine and thyroid hormone 
 
 
 
65 
 
metabolism generates oxidative stress through elevated levels of mitochondrial ROS, but 
we do not know what are the mitochondrial effects of the long-term treatment with iodine 
and TSH suppression, and whether they may contribute to an opposite effect on metabolism 
and ROS generation. Aligned with this apparently paradoxical concept is the evidence 
published by Caino and Altieri (143), where mitochondrial dynamics seems to mediate a 
PI3K therapy adaptive pro-metastatic switch, highlighting why these agents may have not 
been as successful in the clinical practice as the promise of their mechanism of action. 
Finally, we have further explored if the tumor histotype could represent a bias in our results 
in want regards distant metastases, since FTC are known to be more prone to distant 
metastization as compared to PTC. Despite the relatively lower number of FTC patients, we 
did not find any indication that the association vanishes or changes into the opposite side 
of the spectrum. On the contrary, the association was kept, although not statistically 
significant. 
 UCP2 is regulated at both transcriptional and translational levels (141, 144), which 
may explain the nuclear expression of UCP2 which we have found in the tumors from our 
series, and we therefore hypothesize that post-translational modifications may also be 
responsible for the translocation of UCP2 to the nucleus. The gene encoding UCP2 is 
located on chromosome 7 in mice and chromosome 11 in human and contains eight exons 
and seven introns (77). UCP2 promoter gene exhibit different transcription factors binding 
sites such as the specific protein-1 (Sp1) binding site, the sterol regulatory elements (SRE), 
the  peroxisomal proliferators-activated receptors (PPARs), the thyroid hormone response 
elements (TRE), and the E-box (helix-loop-helix protein binding sites) (77). In line with our 
hypothesis above, it would be interesting to further asses the effects of the long-term TSH 
suppression and treatment with iodine on UCP2 expression and function. The transcription 
of UCP2 gene is regulated by several factors such as free fatty acids which establish the 
levels of UCP2 mRNA and, to some extent, the levels of UCP2 protein in several tissues 
(77, 145). UCP2 activity can also be regulated by polyunsaturated fatty acids after being 
translated (146) and by ROS, namely superoxide anion (144), influencing protein 
abundance (77). However, the precise pathway through which superoxide activates UCP2 
is unknown. Indeed, it has been reported that superoxide anion enhances UCP2 which 
supports the theory that the major role of UCP2 is to attenuate the ROS levels. Notably, 
due to translational regulation of UCP2, alterations in mRNA levels do not necessary affect 
UCP2 protein levels. Indeed, Pecqueur et al. demonstrated the presence of UCP2 mRNA 
in mouse heart and skeletal muscle, yet no UCP2 protein was detected in these tissues 
(144). This can be pointed as a limitation of our work since we only determined the amount 
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of UCP2 protein, in a semi-quantitative way, without investigating the amount of UCP2 
mRNA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 - Schematic representation of the possible etiopathogenic role of UCP2 and 
DRP1 in Hürthle cell carcinoma. White box represents initiation and progression stages. 
Light grey box represents generalization stage. 
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6. Conclusions and future perspectives 
 In the present study, we assessed DRP1 and UCP2 expression in a series of 245 
thyroid carcinomas, with and without Hürthle cells. Our results indicate that UCP2 and 
DRP1 are highly expressed in Hürthle cell tumors when compared to non-Hürthle cell 
tumors, a finding that was statistically significant for UCP2. These results underscore the 
role of these proteins in the mitochondrial dynamics. In addition, a positive correlation 
between the expression of both UCP2 and DRP1 in Hürthle and non-Hürthle cell tumors 
was shown, suggesting that DRP1 expression is regulated by UCP2 in both phenotypes. 
Although UCP2 did not seem to associate with any clinical-pathological characteristics of 
poor prognosis, it was negatively associated with the presence of distant metastases. Given 
the recognized role of UCP2 in the attenuation of ROS production, this finding should open 
the hypothesis that distant metastases in thyroid cancer may be linked to the metabolic 
reprogramming of the tumor cells in a way where UCP2, along with DRP1, are no longer as 
relevant for the generalization of the disease as they were in the earlier stages of 
progression and invasion. Knowing that both UCP2 and DRP1 are regulated by post-
translational modifications, and also at a transcriptional level in the case of UCP2, it would 
be interesting to characterize the potential interplay between these mitochondrial proteins’ 
function and tumor molecular traits which are already established as prognosis biomarkers, 
especially the TERT promoter mutations that have been associated to distant metastases, 
and p53 mutations or lack of TP53 expression. Finally, it would be of the upmost relevance 
to further study the effect of iodine treatment and TSH suppression in UCP2 and DRP1, 
and thereby in the mitochondrial bioenergetics and dynamics. This would shed a light into 
the potential mechanisms of iodine treatment resistance and distant metastization, and 
eventually help clinicians to further tailor treatment strategies for those patients that evolve 
as having persistent disease, become refractory to iodine treatment, and will eventually die 
from distant metastization. The concept of interfering with mitochondrial dynamics as a 
strategy to suppress the potential metastatic effect of some targeted therapies has already 
been proposed. Whether this is may be a strategy for the treatment of thyroid cancer is a 
concept that warrants further investigation for a fully defined proof of mechanism. 
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8.2. Appendix 2 – License details for Figure 3 
 
